CUTANEOUS TEST RESULTS - MS AND OTHER DISEASES [57R1]


Erythematous cutaneous reactions (sq. cm.) in persons having MS to


the intradermal injection of thermal antibody-indicating antigen


and of antigen-indicating antibody prepared respectively from


streptococci isolated from the nasopharynxes of persons who had MS,


neuroses, and arthritis:


----------------------------------------------------------------


 Table 1, 57R1 (corrected):    






 Persons who had   Cases Reactions in sq.cm. to I.D. injection of


 multiple sclerosis \/        \/     \/    \/     \/        \/  


                         Antibody-  Antigen-indicating antibody


                        indicating                           


                           antigen  \/    \/     \/        \/


                              \/     


 Type of strain:            Multiple-sclerosis Neurosis Arthritis


 Stain or case #:            8125         7700   8126      8134


 Not receiving


   vaccine or        23      5.75   7.31  9.63   3.14      1.43


   thermal antibody  20      6.25   8.07         5.04      2.15


 Receiving antibody


   and vaccine       13      7.86   3.15         3.85      1.86   -


--------------------------------------------------------------


  "Cutaneous erythematous reactions indicating antibody (5.75 and


6.25 sq. cm.) were significantly less in persons not receiving such


therapeutic injections than in persons receiving such treatment


(7.86 sq.cm.). ...


  "It will be seen that the immediate erythematous reactions to the


intradermal injection of streptococcic antibody (taken to indicate


specific circulating streptococcic antigen in patients not


receiving antibody or vaccine therapeutically) were far greater


(7.31, 8.07, and 9.63 sq. cm.), respectively, than in persons


receiving therapeutic injections of antibody and vaccine (3.15 sq.


cm.). ...


  "Erythematous reactions following intradermal injection of


control antibody solutions were uniformly minimal, but in each of


the three groups having multiple sclerosis reactions were greater


to injections of 'neurotropic' (8126) streptococcic thermal


antibody than to corresponding injections of "arthrotropic" (8134)


antibody prepared respectively from streptococci isolated in studis


of diseases of the nervous system and arthritis."






MS: THERAPEUTIC ADMIN. OF VACCINE & ANTIBODY, DOSE [57R1-783]


"Since such injections were harmless and had to be repeated over


long periods, some members of the family of a nurse was instructed


to give the injections." 57R1






MS: PREFERABILITY OF AUTOGENOUS VACCINE AND ANTIBODY [57R1-784]


"Clinical response to the subcutaneous therapeutic injection of


heterologous streptococcic vaccine ant thermal antibody solutions,


while favorable, was usually not as great nor as constant as it was


to the autogenous preparations." 57R1






ADMINISTRATION OF VACCINE AND ANTIBODY (FOR M.S.)  [57R1]


  "One-tenth milliliter of the autogenous or stock vaccine


containing 200,000,000 streptococci per milliliter isolated from


the nasopharynxes of persons who had multiple sclerosis was


injected subcutaneously for the first injection.  This dose was


increased by 0.1 ml. twice weekly up to the amount of 1 ml.  Then


1 ml. was injected each week for an indefinite period, provided


local and constitutional reactions were minimal and provided


favorable clinical effects occurred.


  "One-half milliliter of the stock or autogenous [multiple


sclerosis] thermal streptococcic antibody from 10 billion


streptococci per milliter was injected separately subcutaneously,


but at the same time or more often, if favorable results ensued. 


This dose was increased to 2 ml. and was given twice weekly or


daily, provided local reactions at the point of injection were


minimal or negative and provided clinical results were favorable."


[57R1]